Vidutolimod Plus Nivolumab Proves Active in High-Risk, Resectable Melanoma
Source: Dermatology Advisor, November 2024
The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.
The trial (NCT03618641) enrolled patients with stage III melanoma. Thirty-one patients were evaluable for efficacy. At baseline, their median age was 62 (range, 19-93) years, and 54.8% were men. Most patients had 1 lesion (58.0%), 25.8% had 2-3 lesions, and 16.2% had more than 3 lesions. Most patients (n=28) had received no prior therapy, 2 had received prior immunotherapy, and 1 had received BRAF/MEK targeted therapy.
On study, patients received neoadjuvant vidutolimod (at 5 mg subcutaneously on week 1 followed by 6 doses of 10 mg intratumorally weekly) and nivolumab (3 doses of 240 mg every 2 weeks). After surgery, patients received vidutolimod (at 5 mg subcutaneously) and nivolumab (at 480 mg every 4 weeks) for up to 1 year.